Objective. To reveal taurine`s effects on metabolism, menstrual and reproductive function in women with PCOS.
Methods. A total of 44 women with PCOS were included in the study with ages ranging from 18 to 44. Patients were randomized into two groups:
1) Dibicor group, n=30;
2) Placebo group, n=14.
Thirty patients received dibicor 500 mg twice a day, fourteen patients received placebo 500 mg twice a day. Duration of the therapy was 3 months. Anthropometric measurements, content of adipose tissue, blood pressure, pulse rate, lipid levels, 3-hours oral glucose tolerance test (OGTT, 75 gr glucose), ultrasound uterine and ovarian investigations were done both before and after the therapy.
Results. In the study group systolic and diastolic blood pressures were decreased. Heart rate was decreased, while serum HDL cholesterol was significantly increased (p=0,03). Changes in glucose metabolism characterized with metabolic clearance improvement in peripheral tissue due to increasing of insulin sensitivity and beta cell function. Modulation of metabolism with taurine was accompanied by ovarian function enhancement, normalization of menstrual cycle, formation of dominate follicle in 20% of women with previous history of anovulation.
Conclusion. Administration of dibicor in women with PCOS modulates metabolic dysfunction and improves reproductive prognosis, and also has protective effects against diabetes and cardiovascular diseases.
Connecting women, science and spirit, the Gynelogic Sunday Supplement delivers a bi-monthly dose of news, views and reviews, as seen through my lady lens.
Connecting women, science and spirit, the Gynelogic Sunday Supplement delivers a bi-monthly dose of news, views and reviews, as seen through my lady lens.
